Born out of a necessity for fiscal sustainability, simulation modeling is playing an increasingly prominent role in setting priorities for combination implementation strategies for HIV treatment and prevention globally. The design of a model and the data inputted into it are central factors in ensuring credible inferences. We executed a narrative review of a set of dynamic HIV transmission models to comprehensively synthesize and compare the structural design and the quality of evidence used to support each model. We included 19 models representing both generalized and concentrated epidemics, classified as compartmental, agent-based, individual-based microsimulation or hybrid in our review. We focused on four structural components (population construction; model entry, exit and HIV care engagement; HIV disease progression; and the force of HIV infection), and two analytical components (model calibration/validation; and health economic evaluation, including uncertainty analysis). While the models we reviewed focused on a variety of individual interventions and their combinations, their structural designs were relatively homogenous across three of the four focal components, with key structural elements influenced by model type and epidemiological context. In contrast, model entry, exit and HIV care engagement tended to differ most across models, with some health system interactions-particularly HIV testing-not modeled explicitly in many contexts. The quality of data used in the models and the transparency with which the data was presented differed substantially across model components. Representative and high-quality data on health service delivery were most commonly not accessed or were unavailable. The structure of an HIV model should ideally fit its epidemiological context and be able to capture all efficacious treatment and prevention services relevant to a robust combination implementation strategy. Developing standardized guidelines on evidence syntheses for health economic evaluation would improve transparency and help prioritize data collection to reduce decision uncertainty.
Key Points
A key challenge in constructing simulation models is the extensive evidence synthesis required to parameterize them. The quality of the evidence used in a model will impact the degree of uncertainty of its outcomes and ultimately the credibility of its inferences. Coyle et al. demonstrated the extent of bias on model outcomes propagated by the use of different underlying data sources within the same modeling framework [12] . HIV simulation models are particularly data intensive due to the need to model both infected and susceptible populations, and the mechanism underlying the force of HIV infection [13, 14] . Local epidemiological and structural factors are also critical in capturing the heterogeneity across regional microepidemics, and ultimately assessing targeted, locally-oriented strategies that are essential to allocate resources effectively and efficiently.
Previous model comparison studies or reviews have focused primarily on differences in model outcomes, aiming to examine whether consistent and robust conclusions can be reproduced across models for a given intervention, with limited discussion on structural characteristics and data quality differences as an explanation for variation in outputs [15] [16] [17] [18] [19] . Two recent HIV model comparison studies [20, 21] have gone beyond simply comparing model predictions, by providing discussion on the differences in several structural attributes that might explain differences in long-term projections. However, as the global public health response moves towards localized combination implementation strategies to combat HIV/AIDS [4, [22] [23] [24] [25] , modelers require more careful consideration of not only the appropriateness of the underlying structural assumptions, but also the quality and context specificity of the data entering models designed to simulate regional contexts.
We executed a narrative review to synthesize and compare a selection of peer-reviewed dynamic HIV transmission models used to facilitate healthcare decision making. Although systematic reviews are often preferred in generating quantitative answers to specific, often narrow, clinical questions of interest (e.g., comparing modeling studies evaluating a given intervention), narrative reviews are useful for obtaining a broader perspective on a topic [26] . We comprehensively assessed the full breadth of each model's structural design and the quality of evidence used to support each model parameter. We then discuss the implications of the choice in model structure and data quality, with the goal of clarifying the implications of these choices for model developers and informing targets for data collection in the future [27] .
Methods

Selection of Relevant Articles
We conducted a comprehensive comparison of recently published simulation models to highlight variation in the To provide credible recommendations for decision makers considering combination implementation strategies to reduce the burden of HIV/AIDS, the structure of simulation models should fit the epidemiological context while capturing all relevant treatment and prevention services. Explicitly reporting and assessing the quality of data entered into a model can improve its replicability and identify focal points for sensitivity analysis and further data collection.
We synthesized information on the structural design and the quality of evidence inputted into 19 high-impact peer-reviewed HIV transmission models and found consistency in model structure but wide disparities in the quality of supporting evidence.
Introduction
Despite substantial investments in the global response to HIV, inadequate and plateauing funding levels [1, 2] increasingly require decision makers to prioritize the allocation of resources available for HIV treatment and prevention. With a number of efficacious behavioral, biomedical and structural interventions available, a combination implementation strategy (the application of multiple treatment and prevention interventions to maximize population-level impact [3] ) has been proposed to reduce the public health burden of HIV/ AIDS [3, 4] . Simulation models can provide a unified framework to quantify the health and economic value of different strategies to address the HIV/AIDS epidemic while accounting for the synergistic effects of different combinations of public health interventions [5] [6] [7] . More than ever before, simulation modeling is playing a critical role in priority setting for HIV treatment and prevention [8] .
Simulation models are simplifications of reality, designed to capture the 'essence' of a problem with a minimally sufficient level of complexity [9] , synthesizing evidence from multiple sources and extrapolating outcomes that may be unavailable, unobservable or unethical to collect [5] . Two key aspects of constructing a model are settling on a structure and gathering evidence to populate it [9, 10] . Determining the structure of a model, including the choice of model type [e.g., compartmental model, agent-based model (ABM)], how the disease process is characterized, and other underlying assumptions should be guided by the decision problem and context [11] .
structural design and quality of data supporting them. Models initially considered for inclusion in our narrative review resulted from a snowball literature search using reference tracking [28] using Eaton et al. [20, 21] and Nosyk et al. [29] as seeds. Simulation modeling studies fulfilling the following selection criteria were included in the review: (1) the model focused on HIV/AIDS explicitly (studies characterizing HIV/AIDS as a coinfection were excluded); (2) the model attempted to reconstruct a real-world population and was applied in solving real-world health decision problems within a dynamic modeling context (thus excluding methodological studies or those focusing on hypothetical settings and populations), excluding those focusing on subsets of the population, e.g., modeling the men who have sex with men (MSM) population exclusively, to ensure the comparability of model structure and evidence requirement; (3) the model was published in the past 10 years, to ensure the protective benefits of antiretroviral therapy (ART) against HIV transmission were captured in the reviewed models; (4) the publication provided sufficient detail (in the manuscript or supporting appendix) to capture the majority of the information required for this review. For studies employing the same or a similar model, only those with the most comprehensive description of model structure and evidence sources for model parameters were retained for review.
Information pertaining to the structural design, underlying assumptions, and data sources was extracted for each model. We stratified the selected models according to the epidemic context for which the model was developed (generalized or concentrated) and the classification of the dynamic model type (i.e., compartmental, individual-based or agentbased) (Table 1) . Data extraction for each component was independently performed by at least two reviewers (XZ, EK, and LW) and any differences were resolved with at least one other author.
Assessment of Model Structure
We extracted information on four structural components [Appendix Fig. A1 , see the electronic supplementary material (ESM)], representing an exhaustive and mutually exclusive description of the structural elements of any HIV simulation models: (1) the population construction, depicting the complexity of a model in characterizing the heterogeneity within the study population; (2) model entry, exit and HIV care engagement, comprising information about how the transitions into and out of the model or any care or treatment programs and associated adverse events were characterized within the model; (3) HIV disease progression, describing health states pertaining to those infected with HIV/AIDS, and the means by which individuals transition between these states; and (4) the force of HIV infection, describing the route(s) of transmission, any factors influencing infectivity, risk behaviors, mixing patterns and biomedical interventions influencing HIV transmission. We note that for each of the studies assessed, we focused exclusively on the underlying structure of the model for the reference case, or comparator strategy, representing the natural state of an HIV epidemic with current levels of availability of HIV treatment and prevention services [30] .
Assessment of Analytical Components
We also extracted information on two analytical components necessary in adhering to best practices in health economic modeling [9] : (1) model calibration/validation, focusing on the selected calibration and validation targets and the methodological approach used in calibrating and validating the model; (2) health economic evaluation, summarizing information relevant to conducting health economic evaluations, including study perspective, cost and utility estimation, an assessment of reporting quality, and a review of uncertainty analysis, focusing on the forms of sensitivity analysis undertaken (deterministic or probabilistic), analyzed parameters and how alternate scenarios to assess the uncertainty of the results were constructed.
Assessment of Quality of Supporting Evidence
We also extracted information about the data sources used to populate the model, where provided. While explicit guidelines for assessing the quality of evidence in simulation models have not yet been developed [31] , we followed Cooper et al. [32] , Zechmeister-Koss et al. [33] and Paisley et al. [34, 35] in defining evidence categories and potential hierarchies of data sources for decision models. We developed a two-dimensional quality assessment framework for HIV simulation modeling (Table 2) , with considerations given to the internal and external validity of the input evidence [36] . Model parameters pertinent to the core components were grouped in eight categories according to these previous attempts, with extensions to some domains of evidence specifically for HIV modeling (e.g., HIV risk behaviors).
First, the internal validity of each parameter in each of the eight categories was assessed and ranked differentially on three levels of quality (best, moderate or lowest) on the basis of best possible study design, given the context. Second, for parameters requiring setting-specific evidence, an assessment of the external validity of each parameter was performed by determining whether the evidence was obtained from a representative study setting. More details about the quality ranking criteria can be found in Appendix Table A1 (see the ESM).
We classified data whose sources were informal or unreported as the lowest quality. In cases where multiple data sources were used for a given parameter, we based our rating on the lowest-quality evidence cited, "as with any model, the results are only as reliable as the model's poorest data input" [32] . We recognized and acknowledged cases where sources were only used to justify prior ranges/distributions for calibrated parameters, and we noted these cases in the according cell while assessing their quality, following the same criteria described above.
Synthesis of Model Structure and Quality of Evidence
We then constructed figures for each of the four structural components (listed in Sect. 2.2) and two analytical components (listed in Sect. 2.3), categorizing information in a common format and noting additional assumptions or information in the footnotes. Within these figures, we color-coded each cell according to the quality of evidence used to inform each design element (Fig. 1 ).
Results
Of the 64 manuscripts (based on 45 HIV simulation models) we identified in our search, 19 met the selection criteria [22, [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] ] (see Fig. 2 for the selection process; results in Table 3 ). Of the 19 models assessed, three adopted an ABM design, two employed an individual-based microsimulation model (IBMM) design, 13 were deterministic compartmental models (DCMs), and one was classified as a combination of an IBMM and DCM design (definition in Table 1 ). Most models were constructed to represent generalized HIV epidemics (13/19) , as opposed to concentrated epidemic settings (6/19) (definition in Table 1 ). Models representing generalized epidemics seemed to favor individual-based designs (i.e., IBMM and ABM, 6/13), which are better suited to capturing heterogeneity in HIV risk behaviors and differences in demographics across the general population, as opposed to compartmental models, which feature more homogeneous behaviors within specified risk groups and thus are better suited to concentrated epidemic settings (6/6). Furthermore, ten models supported what could be considered a formal economic evaluation, comparing both costs and health outcomes of alternative strategies [55] . Three framed their analysis as a constrained optimization problem (including one cost-effectiveness analysis), entailing a decision to be made within budgetary constraints. The remaining were epidemiological models focusing on generating long-term estimates of the epidemiological impact of various public health strategies. The majority of models assessed (15/19) considered at least a 10-year time horizon to capture all meaningful differences in consequences between alternatives considered [9] , particularly regarding the long-term benefits of public health interventions (e.g., ART effectiveness in extending the lives of people living with HIV (PLHIV) and preventing second-and third-order HIV transmission).
Models commonly included three types of comparator strategies: (1) the 'status quo,' capturing the observed scale of existing programs using the most recent data on service delivery; (2) the 'standard of care' whereby health services were characterized strictly as being in compliance with current clinical guidelines; and (3) the 'counterfactual' scenario, assuming the absence of a given intervention.
Population Construction
Model structure Among the 19 reviewed models, many explicitly considered heterogeneity by transmission risk group (5/19), behavioral risk levels within a risk group For example, RCTs, cohort studies, and non-population-based surveys Table 2 (continued) (7/19) , gender (16/19) , and age (8/19) in their population construction (Fig. 3) . Age was usually only accounted for in models explicitly capturing age-dependent sexual risk behavior among heterosexuals (all in generalized epidemic settings in the reviewed studies) [56] [57] [58] . Risk groups were typically determined by routes of HIV transmission. Explicit categories of MSM, people who inject drugs (PWID), and female sex workers (FSW) were typically captured in concentrated epidemic settings (5/6). Heterogeneity in risk behaviors within a population subgroup is often characterized by incorporating multiple risk levels (e.g., high and low risk). This design feature was adopted only in the reviewed DCMs (n = 8). On the contrary, heterogeneity in risk behaviors can, to some extent, be reflected by the stochastic nature of simulating individuals in IBMMs and ABMs [59] .
Once infected, PLHIV progressed through stages of acute infection (12/19), HIV diagnosis (10/19), pre-ART care (4/19), and ART (18/19) . PLHIV were also differentiated by ^M odels that failed to provide sufficient detail (in the manuscript or supporting appendix) to capture the majority of the information required for this review were excluded Objective: estimate the cost-effectiveness and returns on prior investments of HIV prevention programs and identify the optimal allocation of resources across combinations of programs disease progression states. ABMs/IBMMs often parameterized CD4 and/or plasma viral load (pVL) continuously while DCMs stratified them in discrete levels. Some models also incorporated separate states pertinent to ART, e.g., multiple regimen types (6/19, more often in ABMs/IBMMs, 3/6), adverse events (8/19), and dropout (2/19). Quality of evidence Most of the models assessed used the best-quality evidence on population demographics with good external validity, such as a local census database, but only half of the models applied best-quality and settingspecific evidence to initialize the total population size and its distribution across HIV risk groups. Further, estimates for the initial prevalence of the HIV epidemic were mainly populated with local best-quality evidence (14/19) such as national or regional surveillance databases. However, the initial size or distribution of the infected population across each disease state/compartment was often not explicitly reported by the modelers or derived on the basis of seeded simulation, and therefore rated as the lowest-quality evidence used. The quality of evidence was similar among models characterizing generalized and concentrated epidemic contexts.
Model Entry Exit and HIV Care Engagement
Model structure There was considerably less consensus on how to characterize model entry, exit and HIV care engagement in the selected models (Fig. 4) . Most models (16/19) implemented a dynamic study cohort that allowed the population size to change over time, and population entry/ maturation was commonly estimated based on the fraction of individuals who entered or matured out of the defined age group each year or to match the observed population growth or fertility rates. Mortality among the susceptible population was most often dependent on age or gender in ABMs/ IBMMs (5/6) and homogeneous in DCMs (7/13).
HIV testing was explicitly captured in ten models, three of which included symptom-based testing in addition to population-based testing, with six models also accounting for the decrease in HIV risk behavior following diagnosis. Finally, of the 18 models that explicitly integrated ART, ten accounted for both the entry (i.e., initiation) and exit (i.e., dropout) of ART, and ten also accounted for ART-related adverse events explicitly, among which treatment failure was most frequently cited (9/10). ART drop-out rates were modeled as either constant (4/10), time-dependent (4/10), or dependent on other factors (2/10), and half (5/10) also allowed re-initiation after ART dropout.
Quality of evidence Most models based their estimates for cohort entry and exit on the best-quality evidence available locally, such as national or regional census data and life tables, with two models not clearly stating the evidence source for this domain. Data on HIV testing rates were primarily obtained from observational studies based on a The CEPAC model was composed of two modules: the International Module (CEPAC-I), an IBMM, to simulate the disease progression and outcome of disease; and the Transmission Module (CEPAC-T), a DCM, to examine the disease transmission and associated clinical impacts sample of the target population (moderate quality), with only three models using population-based figures from a health system database, such as a health registry/administration database (best quality). The quality for data on HIV testing effect on risk behaviors was also far from ideal, with half using lowest-quality evidence. Finally, less than half of the models used ART initiation and drop-out rates derived from what would be considered best-quality data in this context-a local population-level administrative database or registry-with four basing their estimates on randomized control trials (RCTs) or observational studies conducted within the target population. The evidence source was of low-quality for six out of ten studies capturing ART-related adverse events (including failure, resistance and toxicity). The color schemes presented reflected the evidence used to inform the initial population size of the according compartment or the initial distributions; arabic numbers 2-5 indicate the number of levels for the reviewed item (i.e. risk and CD4). Uppercase letters: C continuous measure of CD4 count or viral load; Ds dichotomous measure of viral load (suppressed or unsuppressed). Lowercase letters: a fertility; b household roles; c PrEP; d sexual activity class; e race; f all the attributes were drawn independently from their empirical distributions; g entry rate adjusted to ensure constant proportions within each sexual risk group; h entry rate adjusted to equivalence in the number of males and females; i (1) age 15-49, sexually active; (2) age ≥ 50 sexually inactive; (3) allowing transitions between risk levels; j allowing transitions between non-PWID and PWID; k (1) retired FSW or clients were the same as low-risk individuals; (2) fixed prevalence of HCV-2; (3) a proportion of people were sexually inactive; l female PWID were not modeled directly; m homogeneity between the susceptible and the undiagnosed. ABM agent-based model, AEs adverse events (including ART failure, resistance and toxicity), ART combination antiretroviral therapy, DCM deterministic compartmental model, FSW female sex workers, HCV-2 hepatitis C genotype 2, Hetero heterosexuals, IBMM individual-based microsimulation model, MMC medical male circumcision, MSM men who have sex with men, OI opportunistic infections, PrEP pre-exposure prophylaxis, PWID people who inject drugs, STI other sexually transmitted infections. The full names of the reviewed models are provided in Table 3 . # Chronic or asymptomatic; *multiple definitions used; **among FSW only; ***among heterosexuals only; ^e quivalent to the three HIV stages; ^^i dentical compartment; ^^^i dentical compartment
HIV Disease Progression
Model structure HIV disease progression was most commonly measured by CD4 cell count (15/19), followed by pVL (7/19) and disease stage, which generally considered acute, chronic, symptomatic and AIDS as health states (14/19) (Fig. 5) . Although there is no explicit consensus on the superiority of these progression measures, many modelers preferred CD4-based HIV progression since it is in alignment with the CD4-based ART eligibility, entailing more precise characterization of treatment initiation (most models were published before the 2015 World Health Organization [WHO] guidelines recommending ART initiation at diagnosis).
Among the 15 models that incorporated CD4-based disease progression, changes in CD4 counts were characterized mainly by two methods: (1) by fitting some linear or nonlinear functions of time or pVL (6/15), as found exclusively in ABMs, IBMMs and DCMs with a stochastic module; or (2) by calculating the progression rate as reciprocal to the time spent between the previous and subsequent CD4 stratum (7/15). Disease progression by change in pVL used explicitly fitted functions in only one model (1/7), unspecified functional form in two (2/7), and the rest altered pVL status for PLHIV receiving treatment (unsuppressed to suppressed) (4/7).
The effect of ART on improving health was captured in 17 out of 19 models, among which ART was assumed to either Fig. 4 Model entry, exit and HIV care engagement. Uppercase letters: A population change was characterized by the estimated rate of aging-in and aging-out into or out of the defined study population age range; G population change was characterized to match observed population growth or fertility rate. Lowercase letters: a infection state, age; b infection state (PB), opportunistic infection state (SB); c opportunistic infection state, age, time-increasing; d time-increasing; e race; f linear time-increasing; g once certain number of years since infection has passed; h as a Hill function increase, with greater rate for CD4 > 200; i estimated number of ART initiations over the annual number of new AIDS cases; j as the reciprocal of the duration between eligibility and treatment; k by the assumed coverage; l regimen; m (1) adherence profile; (2) drug supply; n (1) repeat testing occurred ≥ 1 years for HIV-individuals; (2) longer wait time and lower initiation rate for higher CD4 strata; o (1) linear increase in testing rate with stage number; (2) ART dropout was permanent; p (1) retesting no sooner than every 3 years; (2) treatment stops 3 months after loss to follow-up; (3) ART monitoring occurs every 3-6 months; (4) toxicity: rate varied by time since ART, can trigger 2nd-line ART; q (1) same efficacy for 1st-and 2nd-line ART; (2) toxicity: rate varied by regimen, can cause mortality increase; r (1) testing rates drawn from lognormal distribution; (2) toxicity: rate varied by regimen, can trigger 2nd-line ART; (3) resistance: can be developed (by adherence and number of active drugs) or acquired (by % of resistance presence in the concurrent PLHIV), can reduce number of active drugs; s (1) assuming an ART coverage ceiling as 90%; (2) equal scale-up rate across all locations; t ART provided to CD4 ≥ 350 was considered as TasP and < 350 was considered as treatment; u reinitiation rate varied by CD4, and then back to the normal track as on ART; v (1) ART discontinued PLHIV same as untreated; (2) 2nd-line ART same as 1st-line except in cost; w resistance: homogeneous rate; x (1) ART-failed cases same as untreated; (2) no ART initiation for CD4 > 350; y testing sensitivity and specificity also considered; z (1) same failure rate for 1st-and 2nd-line ART; (2) PLHIV who failed 2nd-line ART were the same as the untreated; aa resource allocation as the sole impetus of testing, and the testing coverage was proxied by the resources allocated. ABM agent-based model, ART antiretroviral therapy, DCM deterministic compartmental model, IBMM individual-based microsimulation model, N/C not clear, OI opportunistic infections, PB population-based, SB symptom-based, TasP treatment as prevention, VL viral load. The full names of the reviewed models are provided in Table 3. # Risk g/l: risk groups or risk levels; *age-, sex-specific migration rate (in and out); **among 50 + only; ***calibrated; ^t he reciprocal of the duration between infection and testing; ^^m eeting failure definition (VL, CD4, OI); ^^^j ointly considered with ART drop-out ◂ reverse (8/17, i.e., CD4 recovery, pVL increase or suppression), delay (4/17, i.e., longer stage period or reduced transition rate), or stop (8/17, i.e., no change in CD4, VL or stage) disease progression. All models accounted for increased mortality for PLHIV, by either assuming excess mortality varied by CD4, HIV stage, age, opportunistic infections, etc. (10/19) or by assuming increased mortality that was restricted to the final stage of disease (e.g., AIDS) (9/19). The direct effect of ART on mortality was more commonly considered in DCMs (10/13) than in ABMs/IBMMs (2/6).
Quality of evidence Only half of the models (9/19) used best-quality evidence to characterize HIV disease progression, and one study [60] was consistently cited for evidence on the time spent in each CD4 stratum or HIV stage (6/19).
Further, none of the models applied best-quality evidence for characterizing the effect of ART on HIV progression, with many (5/17) deriving this effect from observational studies (moderate quality), rather than RCTs. Finally, less than half of the models used best-quality evidence for HIV-related mortality and the effect of ART on mortality, with sources not clearly stated in five models.
The Force of HIV Infection
Model structure First, the infectivity (or susceptibility for the uninfected) was assumed to vary by transmission route (hetero-and homosexual, needle/syringe sharing and mother to child) and be influenced by demographic cofactors (age [3/19] and gender [9/19] ), biological factors (CD4 [6/19] , pVL [3/19] , stage [11/19] , the presence of sexually transmitted infections other than HIV [4/19] ), and other behavioral cofactors (partnership type [4/19] ) (Fig. 6) .
Second, HIV transmission was modeled as a function of the number of partners (sexual or injecting) or partner change rate (14/19), contact frequency (12/19) , and the probability of condom use during sexual contacts (9/19). Differences in risk behaviors across subgroups were considered in almost all models, commonly by age, gender, risk group or risk level, and partnership type. The effects of several biomedical interventions were also incorporated in the force of infection equations, including ART (18/19), medical male circumcision (MMC) (9/19), pre-exposure prophylaxis (PrEP) (2/19) and condom use (8/19) . Finally, all but one model that accounted for partnership mixing (n = 16) constructed preference-based mixing, reflected by a disproportionate likelihood for an individual to select a partner with certain characteristics, such as age (5/16, more in ABMs/IBMMs) and risk group/level (6/16). All ABMs/ IBMMs considered more than one partnership type, while additional non-marital, short-term, casual or commercial partnerships were considered in only four out of 14 DCMs.
Quality of evidence The use of best-quality evidence to inform baseline infectivity through different transmission routes was limited. However, the best-quality evidence for biological factors influencing HIV infectivity was more commonly cited, and one longitudinal study [61] was frequently applied to inform the transmission risk by stages of infection (8/19) . Although many models used best-quality evidence with good external validity such as populationbased behavioral surveillance to populate behavioral parameters, some were obtained strictly through model calibration, where prior ranges were based on assumptions (7/19). Similar categories of evidence sources were used to inform partnership mixing parameters as with other behavioral parameters, whereas the use of lowest-quality evidence was more prevalent. There was also substantial variation in the quality of intervention effect size data; the landmark HTPN-052 study [62] provided best-quality evidence of ART efficacy on reducing transmission risk for most models published afterwards, while none of the assessed models used bestquality evidence to estimate condom efficacy [63] .
Model Analytical Design
Model calibration/validation Calibrating uncertain inputs to known clinical/epidemiological targets and validating a model against external endpoints provides critical tools to enhance readers' confidence in model outcomes and are both recommended by modeling guidelines [64, 65] . Model calibration and validation were both performed only in two out of 19 models, while 12 models incorporated calibration only, two incorporated validation only, and three incorporated neither (Appendix Fig. A2 , see the ESM). Epidemiological endpoints, such as HIV prevalence or incidence, were most often used for setting targets for calibration and validation (14/16), followed by clinical targets (7/16) and demographic targets (4/16). Eleven out of 14 models that incorporated calibration CD4 declines according to a quadratic function with prognosis; (2) total survival time for PLHIV was stochastically sampled from an age-dependent Weibull distribution (with fixed duration for acute and AIDS stages); (3) assuming all new infected cases started with the same initial CD4 counts as 594 cells/mm 3 ; h linear decrease of CD4 in different stages; i CD4 modeled continuously based on VL, and ART; j (1) CD4 decrease determined by VL; (2) progression and clinical events were observed periodically at clinical visits or when OI occurred; k (1) VL changes sampled from normal distribution, CD4 changes by declining rate, adjusted by VL and age; (2) initial VL randomly sampled from log normal distribution, initial CD4: 756 cells/mm 3 ; (3) ART effects on progression varied by number of active drugs and adherence level; l (1) linear decrease of CD4; (2) survival after infection followed a Weibull distribution (with fixed duration for acute and AIDS stages); (3) CD4 decreased by 25% immediately after infection; m (1) PLHIV may enter any CD4 strata after acute stage; (2) CD4 during ART represented the stage to which when treatment being interrupted; n the duration for each stage was exponentially distributed; o (1) post-ART AIDS (treated but unsuppressed) stage is a dead end: no regimen changes allowed; (2) treated and suppressed stage is a dead end: no failure allowed; p % of VL suppression as the multiplication of conditional % of linked to care, % retained to care, % linked to treatment and % achieving suppression; q HSV-2 co-infection assumed to have stable prevalence and increase HIV infectivity. ABM agent-based model, ART antiretroviral therapy, DCM deterministic compartmental model, HSV-2 herpes-simplex virus, IBMM individual-based microsimulation model, N/C not clear, OI opportunistic infections, VL viral load. The full names of the reviewed models are provided in Table 3. # Including CD4 recovery, VL decrease and VL suppression; ## HIVrelated mortality considered for final stage (e.g., AIDS, CD4 < 200) only; *calibrated; **equivalent; ***different progression rate by CD4 strata;
^m ay return to a higher CD4 stratum after dropout; ^^W eibull distribution Fig. 6 The force of HIV infection. Uppercase letters: A age-dependent; G gender-dependent; PT partnership type-dependent; R risk group or risk level-dependent. Lowercase letters: a MTC; b coital type: only the evidence evaluation for its effect on was infectivity shown; the behavioral parameter was based on best quality evidence with lowest external validity; c years since infection; d based on a Spectrum projection (exogenous to the model), influenced by the distribution of CD4 strata due to their distinct infectivity; e probability of needle sharing; f reversely estimated by the observed incidence; g (1) partnership types: transitory, informal, and marital, with different duration (Weibull distribution); (2) assuming exponential distribution of the interval between coital acts; (3) allowing coital dilution for multiple partnerships; h (1) partnership mostly within the community; (2) maximum 2 partners (1 long-term) at a time; (3) allowing external short-term partnership; (4) males tended to be older than females in pairs; i (1) partnership type: marital, casual, commercial; (2) the rate of sex partner change is determined by a supply and demand mechanism (from previous studies) depending on age, sex and marital status; j (1) partnership type: spousal and non-spousal; (2) the risk of having HIV-positive partner was age and gender specific; k partnership type: long-term, short-term; l (1) no interactions between locations; (2) no transmission considered for population aged 50 + ; m partnership type: primary and secondary; n (1) sexual contact rate reduction followed a logistic function ensuring symmetry around the midpoint of behavior change period; (2) number of sexual contacts geometrically adjusted to balance the male and female contacts; o no sexual activity in final AIDS stage; p (1) reduced sexual activity in the wound healing period after MMC; (2) 5% of the partnerships formed with outside partners; q (1) partnership type: marital, casual, commercial; (2) disease advanced PLHIV had reduced sexual behaviors; r frequency of needle sharing decayed over time according to observed trends; s partnership type: occasional commercial, regular commercial, and main; t partnership type: commercial, casual, and regular; u fixed force of infection. ABM agent-based model, ART antiretroviral therapy, DCM deterministic compartmental model, IBMM individual-based microsimulation model, MMC medical male circumcision, MTC mother to child, pref. preference, PLHIV people living with HIV, PrEP pre-exposure prophylaxis, STI sexually transmitted infection, VL viral load. The full names of the reviewed models are provided in Table 3 .
#
Colors indicate the assessment of evidence used to inform the baseline infectivity of different transmission routes; ## number of partners (sexual or injection-sharing), also referred to as the rate of partner change in some models; *all transmission routes were jointly modeled in one force of infection; **the effect of ART on reducing transmission was modeled indirectly through viral load; ^p roportional mixing reported their search algorithms explicitly, where four used a random search (e.g., Latin hypercube sampling), three used a directed search (e.g., Nelder-Mead algorithm), two adopted a Bayesian approach, and one calibrated parameters manually. We note that model parameters chosen for calibration and their evidence quality are explicated in Figs. 3, 4, 5 and 6. Health economic evaluation As noted earlier, ten out of 19 reviewed models adopted a formal health economic evaluation, with another two constrained optimization models that incorporated costs (Fig. 7) . Among the 12 models incorporating costs, two out of 12 adopted the broadest societal perspective, and seven framed their analysis from the perspective of service provider or public health, scrutinizing costs only borne by the healthcare system, whereas three models did not explicitly report their perspectives. Further, treating and preventing HIV may involve a variety of costs: (1) direct medical costs (e.g., costs for HIV testing, HIV care, ART, preventative drugs, treatment to comorbidities), considered in 12 out of 12 models; (2) direct non-medical costs (e.g., costs for program operation, education, capital), considered in three out of 12 models; and (3) indirect costs (e.g., productivity loss due to HIV infection), considered in no models (including the two stating a societal perspective). Finally, six out of ten models supporting a health economic evaluation used quality-adjusted life years (QALYs) or disability-adjusted life year (DALYs), as their measures of health outcomes. We also provided an assessment of the quality of reporting among these 19 models by determining whether they met recommendations for each of the CHEERS Checklist items [66] , and we found most models upheld a high level of quality in reporting (Appendix Fig. A4 , see the ESM).
Uncertainty analysis is another recommended component of simulation modeling that quantifies the uncertainty of model outputs, enabling decision makers to gauge confidence and identify targets for future research/data collection [64] . However, five out of 19 reviewed models did not report any form of uncertainty (Appendix Fig. A3 , see the ESM). Among the 14 models assessing uncertainty, four executed more than one type of analysis, and most models quantified uncertainty deterministically, particularly by one-way sensitivity analysis (7/14) , while only four conducted probabilistic sensitivity analysis.
Quality of evidence Only half of the models (6/12) derived costs/resource utilization from best-quality evidence (prospectively collected or from reliable databases), while the rest based their cost data mainly on other economic evaluation or cost studies. Similarly, only three out of six models used best-quality evidence for health state utility, with one out of three prospectively collected and assessed, one out of three from a metaanalysis, and one out of three from an existing utility repository.
Discussion
We have provided a detailed assessment of the structural design and quality of evidence supporting 19 HIV/AIDS simulation models. We found consistency in model types Table 3 . # Also including modified societal; ## e.g., capital cost, program operational cost, research cost; *e.g., productivity loss according to epidemic context (i.e., generalized versus concentrated), but identified some key structural differences, particularly in characterizing the level of availability of effective HIV treatment and prevention services, a finding which has important implications for guiding combination implementation strategies. Otherwise, there was generally less consistency in the quality of evidence used to inform models, particularly with respect to risk group classification, parameters capturing health system engagement (e.g., HIV testing, ART engagement), and several intervention effect sizes (e.g., condom efficacy, ART effect on disease progression). The lack of explicit guidelines in data identification and quality assessment likely contributed to these inconsistencies; however, our results also suggest several key data points are not routinely or systematically collected in many jurisdictions.
A key finding of this review was that HIV testing was not modeled explicitly in almost half of the reviewed models. HIV testing initiatives have been shown to be cost-effective [67] [68] [69] , and explicitly modeling testing provides the opportunity to account for changes in risk behaviors following testing [70] [71] [72] , and the odds of subsequent ART initiation [73, 74] . Although many of the models we assessed were purpose-built to evaluate one or several specific interventions, it is critical to note that individual interventions may be enhanced or diminished when delivered in combination with others. For example, while the benefits of ART are well-documented, the effect of treatment interventions may only be maximized in combination with a sufficient level of HIV testing. There is a growing recognition of the critical importance of combination HIV prevention in achieving epidemic control [3, 75] . In the context of informing combination implementation strategies, in general, focusing on individual interventions or selected combinations may obscure the value of other efficacious interventions, and may constrain a model's capacity to identify the highest-valued combination strategies [4] .
Another key finding of our review was that the highestquality local administrative/registry data was often unavailable or otherwise not cited. Instead, some models based their estimates for elements like the HIV testing rate, ART initiation, and retention in care on sample-based observational studies or RCTs. Similarly, while readily available, high-quality census data were used in most models to inform population-level demographic parameters, only half of the models used best-quality, setting-specific evidence to derive initial values for the size of risk groups or for the distribution of people at different levels of risk for HIV infection. Routinely collected surveillance and administrative data can provide reliable, population-based healthcare utilization and behavioral data that could enhance a model's validity. The infrastructure to facilitate this level of data collection is, however, costly to construct and may be infeasible in some settings. Sensitivity analysis is recommended by best practice guidelines to address concerns regarding parameter uncertainty [64, 76] , and 14 out of 19 of the studies we reviewed featured some form of sensitivity analysis. Further, 14 out of 19 of the studies we assessed set parameters with the greatest uncertainty as 'free' parameters in calibration, which also constitutes recommended practice [64, 76] . However, it should be clear that better quality evidence is preferable even in setting ranges for calibration and sensitivity analysis. Value of information analysis [77] -built on the level and source of uncertainty in cost-effectiveness analyses-can guide efforts to ensure the limited resources available for data collection are focused on the most influential parameters, thus reducing uncertainty in resource allocation decisions to the greatest possible extent [27] . These features are integral to producing valid representations of local contexts and should be a focal point for analysts moving forward.
While the models we assessed generally upheld a high level of transparency in their descriptions of model structure, we found more substantial variation in the reporting of data sources and their selection, particularly as the evidence dictating the initialization of the infected population (at each state) was often underreported. Likewise, in contrast to a number of best practice guidelines informing model design, there is less consensus on the practical and methodological challenges related to the use of evidence in simulation models, including (1) the definition and identification of 'relevant' evidence, (2) the assessment of evidence quality, and (3) the synthesis of evidence [31] . Only one [53] of the 19 reviewed models explicitly presented its process of systematic evidence gathering, whereas in most models, quality assessment and how evidence was synthesized were unclear. Explicitly reporting and assessing the quality of data entered into a model can improve its replicability and identify focal points for sensitivity analysis and further data collection. The quality assessment framework (Table 2) we have proposed can contribute to the development of standardized approaches to identifying and assessing the quality of model inputs in the application of model development or critical review. For example, this framework can be used to structure and formalize the evidence synthesis supporting a modeling study, increasing transparency, rigor and ultimately credibility. It can also help identify parameters with the greatest uncertainty, which should be targets for calibration, sensitivity analysis or further value of information analysis.
In deliberations on model complexity and intensity of data requirements, researchers need to find the right balance between parsimony and complexity, as every additional parameter could introduce new sources of uncertainty and can potentially have a counterintuitive effect on model results [78] . Complex models are not necessarily more accurate or reliable than simpler ones that are developed with high-quality data. Rather, models should only be sufficiently complex to address the policy question and key epidemiological features, with careful consideration of the availability and quality of data. Sensitivity analysis on model structure could be used to identify the degree of parsimony in a model, by ensuring conclusions and the degree of uncertainty are robust to changes in model structure [78] . We did not attempt to make a judgement on what constitutes a sufficient level of complexity for a given context and research question. This qualitative description of the models we have selected provides a guide for model developers to consider when determining the most appropriate and feasible design. We believe this type of review, with explicit focus on structure and data quality can be useful across disease areas, particularly those with fewer historical precedents or where data are more sparse.
This narrative review has several potential limitations. First, the selection of models was not systematic. Given the large amount of existing HIV models and the breadth and depth of this review, we believe a narrative review was most practical and appropriate for our aims. The snowball sampling approach we undertook, which included a majority of HIV models in the HIV Modeling Consortium database [79] , was designed to yield a group of highly influential models representing various typologies, geographic and application contexts currently used in practice, though they may not be representative of all HIV models published within the study timeframe. It was not our intention to exhaustively detail the structural design characteristics and their underlying data for all published models in HIV, but rather underline areas of consensus and divergence on key aspects of model development; we have been careful to avoid sweeping conclusions that would require a systematic review. By explicating different structural/analytical designs and sources/ quality of data in the selected models, we hope this review can provide guidance for model developers in selecting an appropriate model structure, identifying data sources and assessing uncertainty, as well as guidance for reviewers critically assessing HIV modeling applications. Second, the internal validity of evidence quality was only assessed by study design rather than a full investigation of the quality of source study. While there is certainly room for greater scrutiny in this domain, we believe even a limited assessment of evidence quality can improve the rigor and credibility in simulation modeling. Finally, several aspects of modeling were not covered in this review, such as the interventions being evaluated and the prognosis of comorbid conditions, as these were beyond the scope of this exercise. Rather, we focused on assessing the structural design and quality of evidence used in the reference case, whose implications are generalizable to all HIV modeling regardless of context or decision problem.
Conclusion
Simulation modeling has become an indispensable tool in evidence-based decision making [9] , particularly in the public health response to HIV/AIDS where significant investment still needs to be made to reach international targets. We believe this narrative review advances the ability of model developers to critically select and assess the appropriate model structure for a given epidemiological context, as well as the corresponding data requirements. Formal assessment of the influence of poorer-quality data on model inferences should be used to guide decisions to collect more data, in the interest of reducing decision uncertainty. Finally, developing guidelines on evidence syntheses supporting decision models, with an emphasis on quality assessment, should be a priority in the field.
